{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T20:05:53Z","timestamp":1790193953676,"version":"4.1.0"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2018,11,9]],"date-time":"2018-11-09T00:00:00Z","timestamp":1541721600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Thymic atypical carcinoid (TAC) is a rare thymic neuroendocrine tumor that originates in the neuroendocrine system and lacks a standardized treatment. The combination of capecitabine (CAP) and temozolomide (TEM) is associated with an extremely high and long-lasting response rate in patients with metastatic pancreatic neuroendocrine tumors. However, there is little evidence showing that the CAPTEM regimen is effective for TAC. For patients with unresectable or metastatic atypical carcinoid of the thymus, few treatment options are available, and the treatment efficacy is not satisfactory. To explore the efficacy and safety of the CAPTEM regimen against TAC, we conducted a retrospective review.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Patients and Methods<\/jats:title>\n                  <jats:p>A total of nine patients with advanced atypical carcinoid of the thymus in the China-Japan Friendship Hospital were treated with capecitabine (750 mg\/m2 twice daily, days 1\u201314) and temozolomide (200 mg\/m2 once daily, days 10\u201314) every 28 days between 2014 and 2018. The disease control rate (DCR), progression-free survival (PFS), and adverse effects after treatment were analyzed. The DCR was calculated by RECIST version 1.1. Progression-free survival was calculated by the Kaplan-Meier survival method.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of nine patients (six male and three female) were included. The median age at CAPTEM initiation was 50 years (range, 26\u201358). The median number of CAPTEM cycles was 8 (range, 3\u201323). The DCR was 89% (8\/9), with eight patients achieving stable disease. Only one patient (11%) showed progressive disease. The median PFS was 8 months. Because we applied vitamin B6 and ondansetron before administering the drugs, the side effects of this regimen were very small. Adverse reactions were all below grade 3 and included myelosuppression and digestive tract reaction.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Our results suggest that the CAPTEM regimen may be effective and well tolerated for the treatment of TAC. More evidence is needed to validate the effectiveness of this regimen.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1634\/theoncologist.2018-0291","type":"journal-article","created":{"date-parts":[[2018,11,9]],"date-time":"2018-11-09T15:45:19Z","timestamp":1541778319000},"page":"798-802","source":"Crossref","is-referenced-by-count":12,"title":["Capecitabine and Temozolomide as a Promising Therapy for Advanced Thymic Atypical Carcinoid"],"prefix":"10.1093","volume":"24","author":[{"given":"Xin","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Integrative Oncology, China-Japan Friendship Hospital, Beijing, People's Republic of China"},{"name":"Beijing University of Chinese Medicine, Beijing, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanliang","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Integrative Oncology, China-Japan Friendship Hospital, Beijing, People's Republic of China"},{"name":"Beijing University of Chinese Medicine, Beijing, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianghui","family":"Duan","sequence":"additional","affiliation":[{"name":"Department of Radiology, China-Japan Friendship Hospital, Beijing, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingying","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Integrative Oncology, China-Japan Friendship Hospital, Beijing, People's Republic of China"},{"name":"Beijing University of Chinese Medicine, Beijing, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Yuan","sequence":"additional","affiliation":[{"name":"Department of Integrative Oncology, China-Japan Friendship Hospital, Beijing, People's Republic of China"},{"name":"Beijing University of Chinese Medicine, Beijing, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhirong","family":"Qi","sequence":"additional","affiliation":[{"name":"Department of Integrative Oncology, China-Japan Friendship Hospital, Beijing, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huangying","family":"Tan","sequence":"additional","affiliation":[{"name":"Department of Integrative Oncology, China-Japan Friendship Hospital, Beijing, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,11,9]]},"reference":[{"key":"2021122507021193800_R1","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/modpathol.3880423","article-title":"Clinicopathologic and DNA cytometric analysis of carcinoid tumors of the thymus","volume":"14","author":"Goto","year":"2001","journal-title":"Mod Pathol"},{"key":"2021122507021193800_R2","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1016\/S0003-4975(02)03547-6","article-title":"Primary neuroendocrine tumors of the thymus","volume":"74","author":"Chaer","year":"2002","journal-title":"Ann Thorac Surg"},{"issue":"suppl 15","key":"2021122507021193800_R3","doi-asserted-by":"crossref","first-page":"S1448","DOI":"10.21037\/jtd.2017.02.02","article-title":"Neuroendocrine tumors of the thymus and mediastinum","volume":"9","author":"Bohnenberger","year":"2017","journal-title":"J Thorac Dis"},{"key":"2021122507021193800_R4","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1097\/JTO.0000000000000654","article-title":"The 2015 World Health Organization Classification of Tumors of the Thymus: Continuity and changes","volume":"10","author":"Marx","year":"2015","journal-title":"J Thorac Oncol"},{"key":"2021122507021193800_R5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.hoc.2015.08.005","article-title":"Pathologic classification of neuroendocrine neoplasms","volume":"30","author":"Klimstra","year":"2016","journal-title":"Hematol Oncol Clin North Amer"},{"key":"2021122507021193800_R6","doi-asserted-by":"crossref","first-page":"2986","DOI":"10.1158\/1078-0432.CCR-06-2053","article-title":"Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors","volume":"13","author":"Ekeblad","year":"2007","journal-title":"Clin Cancer Res"},{"key":"2021122507021193800_R7","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1200\/JCO.2005.03.6046","article-title":"Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors","volume":"24","author":"Kulke","year":"2006","journal-title":"J Clin Oncol"},{"key":"2021122507021193800_R8","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.1200\/JCO.2011.40.3147","article-title":"Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors","volume":"30","author":"Chan","year":"2012","journal-title":"J Clin Oncol"},{"issue":"suppl 16","key":"2021122507021193800_R9","doi-asserted-by":"crossref","first-page":"4216A","DOI":"10.1200\/jco.2005.23.16_suppl.4216","article-title":"Effective treatment of neuroendocrine tumors with temozolomide and capecitabine","volume":"23","author":"Fine","year":"2005","journal-title":"J Clin Oncol"},{"key":"2021122507021193800_R10","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1245\/s10434-008-0261-z","article-title":"In vitro chemoresistance testing in well-differentiated carcinoid tumors","volume":"16","author":"Lyons","year":"2009","journal-title":"Ann Surg Oncol"},{"key":"2021122507021193800_R11","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1002\/cncr.25425","article-title":"First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas","volume":"117","author":"Strosberg","year":"2011","journal-title":"Cancer"},{"key":"2021122507021193800_R12","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1002\/1097-0142(197204)29:4<1061::AID-CNCR2820290456>3.0.CO;2-3","article-title":"Mediastinal endocrine neoplasm, of probable thymic origin, related to carcinoid tumor. Clinicopathologic study of 8 cases","volume":"29","author":"Rosai","year":"1972","journal-title":"Cancer"},{"key":"2021122507021193800_R13","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1200\/JCO.2007.15.4377","article-title":"One hundred years after \u201ccarcinoid\u201d: Epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States","volume":"26","author":"Yao","year":"2008","journal-title":"J Clin Oncol"},{"key":"2021122507021193800_R14","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1097\/SLA.0b013e3181dd4ec4","article-title":"Thymic neuroendocrine tumors: A SEER database analysis of 160 patients","volume":"251","author":"Gaur","year":"2010","journal-title":"Ann Surg"},{"key":"2021122507021193800_R15","doi-asserted-by":"crossref","first-page":"e7842","DOI":"10.1097\/MD.0000000000007842","article-title":"Treatment, prognostic markers, and survival in thymic neuroendocrine tumors: A single center experience of 41 patients","volume":"96","author":"Ma","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"2021122507021193800_R16","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1309\/3PDN-PMT5-EQTM-H0CD","article-title":"Neuroendocrine carcinomas (carcinoid tumor) of the thymus. A clinicopathologic analysis of 80 cases","volume":"114","author":"Moran","year":"2000","journal-title":"Am J Clin Pathol"},{"key":"2021122507021193800_R17","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1378\/chest.124.1.141","article-title":"A clinicopathologic study of 12 neuroendocrine tumors arising in the thymus","volume":"124","author":"Tiffet","year":"2003","journal-title":"Chest"},{"key":"2021122507021193800_R18","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.1210\/jc.2014-1560","article-title":"Natural course and survival of neuroendocrine tumors of thymus and lung in MEN1 patients","volume":"99","author":"Laat","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"2021122507021193800_R19","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1111\/cen.13480","article-title":"Clinical features and prognosis of thymic neuroendocrine tumours associated with multiple endocrine neoplasia type 1: A single-centre study, systematic review and meta-analysis","volume":"87","author":"Ye","year":"2017","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2021122507021193800_R20","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s00280-012-2055-z","article-title":"Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience","volume":"71","author":"Fine","year":"2013","journal-title":"Cancer Chemoth Pharm"},{"key":"2021122507021193800_R21","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1097\/MPA.0000000000000174","article-title":"Efficacy of capecitabine and temozolomide combination in well-differentiated neuroendocrine tumors: Jordan experience","volume":"43","author":"Abbasi","year":"2014","journal-title":"Pancreas"},{"key":"2021122507021193800_R22","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1634\/theoncologist.2015-0470","article-title":"The role of capecitabine\/temozolomide in metastatic neuroendocrine tumors","volume":"21","author":"Ramirez","year":"2016","journal-title":"The Oncologist"},{"key":"2021122507021193800_R23","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1530\/ERC-16-0147","article-title":"Analysis of potential response predictors to capecitabine\/temozolomide in metastatic pancreatic neuroendocrine tumors","volume":"23","author":"Cives","year":"2016","journal-title":"Endocr Relat Cancer"},{"key":"2021122507021193800_R24","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1159\/000345938","article-title":"Treatment of metastatic neuroendocrine tumors of the thymus with capecitabine and temozolomide: A case series","volume":"97","author":"Saranga-Perry","year":"2013","journal-title":"Neuroendocrinology"},{"key":"2021122507021193800_R25","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1158\/1078-0432.CCR-08-1476","article-title":"O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors","volume":"15","author":"Kulke","year":"2009","journal-title":"Clin Cancer Res"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2018-0291","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2018-0291","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/24\/6\/798\/41918414\/oncolo_24_6_798.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/24\/6\/798\/41918414\/oncolo_24_6_798.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,25]],"date-time":"2021-12-25T07:03:15Z","timestamp":1640415795000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/24\/6\/798\/6439380"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,9]]},"references-count":25,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2018,11,9]]},"published-print":{"date-parts":[[2019,6,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2018-0291","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,6,1]]},"published":{"date-parts":[[2018,11,9]]}}}